Technical Analysis for KYKOF - Kyowa Hakko Kogyo

Grade Last Price % Change Price Change
grade A 25.49 18.56% 3.9900
KYKOF closed up 18.56 percent on Friday, July 17, 2020, on 2 percent of normal volume. The bulls were able to push the stock to a new 52-week high. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical KYKOF trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
Expansion Breakout Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week High Strength 0.00%
Stochastic Reached Overbought Strength 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Gapped Up Strength 0.00%
Overbought Stochastic Strength 0.00%
Narrow Range Bar Range Contraction 18.56%
Older signals for KYKOF ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Kyowa Hakko Kirin Co., Ltd., a research and development-based life sciences company, manufactures and markets pharmaceuticals and bio-chemicals worldwide. Its products include ABSTRAL, a novel sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; GRAN, a human colony-stimulating factor; and G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia. The company's products also comprise LEUNASE for acute lymphoblastic leukemia; Mitomycin-C, an anticancer antibiotic; Moventig for the treatment of opioid induced constipation in adult patients; PecFent, a nasally administrated spray; and REGPARA, a new class of agent for the treatment of secondary hyperparathyroidism. In addition, it offers Romiplate/Nplate, a genetically recombinant protein, which stimulates platelet production through the stimulation of thrombopoietin receptors; and SANCUSO for the treatment for nausea and vomiting. The company was founded in 1949 and is headquartered in Tokyo, Japan. Kyowa Hakko Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
Medicine Biotechnology Cancer Pharmaceuticals Biology Chemotherapy Hypertension Allergies Constipation Nausea Cytokines Vomiting Acute Lymphoblastic Leukemia Amgen Angina Pectoris Growth Factors Kirin Secondary Hyperparathyroidism Bio Chemicals Breakthrough Pain Erythropoiesis Stimulating Agent Kirin Holdings Kyowa Hakko Kirin

Is KYKOF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Indicators

Indicator Value
52 Week High 25.49
52 Week Low 13.25
Average Volume 6,556
200-Day Moving Average 17.6672
50-Day Moving Average 18.9274
20-Day Moving Average 20.3640
10-Day Moving Average 22.0240
Average True Range 1.0440
ADX 18.0
+DI 64.4322
-DI 32.0676
Chandelier Exit (Long, 3 ATRs ) 22.3580
Chandelier Exit (Short, 3 ATRs ) 20.0020
Upper Bollinger Band 24.3859
Lower Bollinger Band 16.3421
Percent B (%b) 1.14
BandWidth 39.5001
MACD Line 1.1638
MACD Signal Line 0.8400
MACD Histogram 0.3238
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.4900
Resistance 3 (R3) 25.4900 25.4900 25.4900
Resistance 2 (R2) 25.4900 25.4900 25.4900 25.4900
Resistance 1 (R1) 25.4900 25.4900 25.4900 25.4900 25.4900
Pivot Point 25.4900 25.4900 25.4900 25.4900 25.4900
Support 1 (S1) 25.4900 25.4900 25.4900 25.4900 25.4900
Support 2 (S2) 25.4900 25.4900 25.4900 25.4900
Support 3 (S3) 25.4900 25.4900 25.4900
Support 4 (S4) 25.4900